709 studies found for:    trastuzumab
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
2 Recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Conditions: Bone Metastases;   HER2-positive Breast Cancer;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Soft Tissue Metastases;   Stage IV Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Biological: trastuzumab;   Radiation: copper Cu 64-DOTA-trastuzumab;   Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis
3 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
4 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
5 Completed A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Condition: Healthy
Interventions: Biological: PF-05280014;   Biological: Herceptin
6 Completed
Has Results
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
7 Active, not recruiting Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
8 Recruiting A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).
Condition: Brest Cancer
Interventions: Drug: Trastuzumab subcutaneous inyection vial;   Device: Trastuzumab subcutaneous device administration
9 Recruiting Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Trastuzumab
10 Active, not recruiting Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: PF03512676;   Other: Correlative Studies
11 Active, not recruiting Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Trastuzumab
12 Terminated Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Condition: Metastatic Breast Cancer
Interventions: Drug: G-CSF;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: saline
13 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
14 Recruiting Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Conditions: Metastatic Breast Cancer;   Carcinomatous Meningitis
Intervention: Drug: Trastuzumab
15 Recruiting Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab
16 Recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
17 Recruiting NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Condition: HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab
Interventions: Drug: BKM120;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
18 Active, not recruiting A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Condition: Advanced Breast Cancer
Interventions: Drug: HKI-272;   Drug: Herceptin
19 Completed Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Condition: Advanced Cancers
Interventions: Drug: Pazopanib;   Drug: Lapatinib;   Drug: Trastuzumab (Herceptin®)
20 Completed 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
Condition: Breast Cancer
Intervention: Other: Imaging with 89Zr-trastuzumab PET

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years